ICU Medical (NASDAQ:ICUI) Stock Rating Lowered by StockNews.com

StockNews.com downgraded shares of ICU Medical (NASDAQ:ICUI) from a buy rating to a hold rating in a report issued on Tuesday morning.

Several other analysts also recently issued reports on ICUI. Jefferies Financial Group began coverage on ICU Medical in a research note on Monday, October 14th. They set a “hold” rating and a $183.00 target price on the stock. Raymond James increased their target price on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research report on Thursday, October 10th. Finally, KeyCorp raised their price target on ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, ICU Medical currently has an average rating of “Moderate Buy” and a consensus price target of $173.00.

ICU Medical Stock Performance

Shares of ICUI opened at $167.86 on Tuesday. The firm has a market cap of $4.11 billion, a P/E ratio of -36.73 and a beta of 0.66. ICU Medical has a twelve month low of $82.82 and a twelve month high of $196.26. The firm’s 50 day moving average price is $176.43 and its two-hundred day moving average price is $142.68. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.08 and a current ratio of 2.29.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Tuesday, November 12th. The medical instruments supplier reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.35. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. The business had revenue of $580.07 million during the quarter, compared to the consensus estimate of $574.77 million. On average, analysts forecast that ICU Medical will post 3.81 EPS for the current fiscal year.

Insider Activity

In other news, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $18,665,666.78. This represents a 10.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Daniel Woolson sold 2,502 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the transaction, the vice president now directly owns 13,107 shares in the company, valued at approximately $2,139,324.54. This trade represents a 16.03 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,502 shares of company stock valued at $6,573,496. Company insiders own 6.70% of the company’s stock.

Institutional Trading of ICU Medical

Institutional investors have recently made changes to their positions in the company. Allworth Financial LP lifted its position in shares of ICU Medical by 100.0% during the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 100 shares during the last quarter. Xponance Inc. lifted its stake in shares of ICU Medical by 6.0% during the second quarter. Xponance Inc. now owns 1,977 shares of the medical instruments supplier’s stock valued at $235,000 after buying an additional 112 shares during the period. Equitable Trust Co. raised its stake in ICU Medical by 2.2% during the third quarter. Equitable Trust Co. now owns 5,213 shares of the medical instruments supplier’s stock worth $950,000 after purchasing an additional 112 shares during the period. CWM LLC grew its holdings in ICU Medical by 18.5% during the 2nd quarter. CWM LLC now owns 767 shares of the medical instruments supplier’s stock valued at $91,000 after purchasing an additional 120 shares in the last quarter. Finally, Hexagon Capital Partners LLC raised its stake in shares of ICU Medical by 162.7% in the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 122 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.